Compugen Ltd.
AI-driven discovery of novel antibody therapies for cancer immunotherapy.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in drug discovery and development. The company utilizes its proprietary, AI/ML-powered computational discovery platform, Unigen™, to identify novel drug targets and biological pathways. Compugen's primary focus is on developing a pipeline of first-in-class therapeutic antibodies to provide new treatment options for cancer patients who are unresponsive or refractory to existing therapies. The company is a pioneer in its field, with a significant discovery being the PVRIG immune checkpoint pathway, which it is targeting to enhance patient responses to cancer immunotherapies.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Compugen Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-17 16:00 |
Foreign Filer Report
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
|
English | 106.4 KB | |
| 2025-09-17 16:00 |
Foreign Filer Report
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
|
English | 36.3 KB | |
| 2025-09-08 16:00 |
Regulatory News Service
to Present Research at the Single Cell Genomics 2025 Conference
|
English | 94.0 KB | |
| 2025-09-08 16:00 |
Foreign Filer Report
to Present Research at the Single Cell Genomics 2025 Conference
|
English | 36.5 KB | |
| 2025-08-28 16:00 |
Regulatory News Service
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Confer…
|
English | 95.5 KB | |
| 2025-08-28 16:00 |
Foreign Filer Report
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Confer…
|
English | 36.4 KB | |
| 2025-08-06 16:30 |
Foreign Filer Report
Immediate Report of Meeting to be held on September 16, 2025
|
English | 255.1 KB | |
| 2025-08-06 16:30 |
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on September 16, 2025
|
English | 160.4 KB | |
| 2025-08-06 16:00 |
Foreign Filer Report
Compugen Reports Second Quarter 2025 Results
|
English | 1.4 MB | |
| 2025-08-06 16:00 |
Foreign Filer Report
Compugen Reports Second Quarter 2025 Results
|
English | 36.3 KB | |
| 2025-07-28 16:00 |
Regulatory News Service
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resi…
|
English | 93.6 KB | |
| 2025-07-28 16:00 |
Foreign Filer Report
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resi…
|
English | 36.5 KB | |
| 2025-07-23 16:00 |
Report Publication Announcement
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference…
|
English | 91.0 KB | |
| 2025-07-23 16:00 |
Report Publication Announcement
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference…
|
English | 36.4 KB | |
| 2025-07-21 16:00 |
Foreign Filer Report
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Plati…
|
English | 468.1 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
